Pulipati Vishnu Priya, Davidson Michael H
Preventive Cardiology, Section of Cardiology, The University of Chicago, 5841 S Maryland Avenue, MC 6080 B-608A, Chicago, IL 60637, USA.
Future Cardiol. 2021 Oct;17(7):1249-1260. doi: 10.2217/fca-2020-0153. Epub 2021 Jan 19.
Dyslipidemia promotes atherosclerosis and causes cardiovascular diseases. Statins are potent lipid-lowering medications with a cardiovascular mortality benefit. They are generally safe and well tolerated but sometimes can be associated with side effects of variable severity. The most common side effect is statin-associated muscle symptoms. Uncommon side effects include new-onset diabetes mellitus and elevation in liver enzymes. These effects can lead to noncompliance and premature discontinuation of the medication. Hence, it is crucial to identify patients with true statin-associated side effects (SASE) to ensure optimal statin use. The appropriate evaluation of the patient before starting statins and proactive utilization of available diagnostic tests to rule out alternate etiologies mimicking adverse effects are essential for accurate diagnosis of SASE. In patients with true SASE, timely intervention with modified statin or non-statins is beneficial. Herein, we discuss key clinical trial data on statins and non-statins, and describe our center's approach toward patients with SASE.
血脂异常会促进动脉粥样硬化并引发心血管疾病。他汀类药物是强效降脂药物,对降低心血管疾病死亡率有益。它们通常安全且耐受性良好,但有时可能会伴有严重程度不一的副作用。最常见的副作用是他汀类药物相关的肌肉症状。罕见的副作用包括新发糖尿病和肝酶升高。这些影响可能导致患者不依从治疗并过早停药。因此,识别真正有他汀类药物相关副作用(SASE)的患者以确保他汀类药物的最佳使用至关重要。在开始使用他汀类药物之前对患者进行适当评估,并积极利用可用的诊断测试排除模仿不良反应的其他病因,对于准确诊断SASE至关重要。对于真正有SASE的患者,及时使用调整后的他汀类药物或非他汀类药物进行干预是有益的。在此,我们讨论关于他汀类药物和非他汀类药物的关键临床试验数据,并描述我们中心对有SASE患者的处理方法。